home / stock / fulc / fulc news

FULC News and Press, Fulcrum Therapeutics Inc. From 09/07/23

Stock Information
Company Name: Fulcrum Therapeutics Inc.
Stock Symbol: FULC
Market: NYSE
Website: fulcrumtx.com
Menu
FULC FULC Quote FULC Short FULC News FULC Articles FULC Message Board
Get FULC Alerts

News, Short Squeeze, Breakout and More Instantly...
FULC - Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Pha...
FULC - MVIS, DHC and RUM are among after hour movers

2023-08-28 17:17:30 ET Gainers: Fate Therapeutics ( NASDAQ: FATE ) +5% . Diversified Healthcare  ( DHC ) +4% . Taysha Gene Therapies ( TSHA ) +3% . Afya ( AFYA ) +3% . Iris Energy ( IREN ) +2% . Losers: Kodiak Sc...

FULC - OIG, ARMP and ULBI among mid-day movers

2023-08-22 12:47:19 ET Gainers: VinFast Auto ( VFS ) +123% . AMTD Digital ( HKD ) +67% . Fulcrum Therapeutics ( FULC ) +51% . Hitek Global ( HKIT ) +30% . Fabrinet ( FN ) +28% . BioNexus Gene Lab Corp. ( BGLC ) +22% ....

FULC - Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near Top of Volume Charts in Tuesday Trading

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is one today's most active stocks by volume. So far today, approximately 63.93M shares of Fulcrum Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 787.16k shares. Fulcrum Therapeutics, Inc., a clinical-stage biopharmac...
FULC - Fulcrum upgraded to buy at Stifel on ending of clinical hold

2023-08-22 11:56:20 ET More on Fulcrum Therapeutics Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD Fulcrum inks licensing deal for rare blood disorder Fulcrum slips as Goldman Sachs downgrades on limited catalyst path Seeking A...

FULC - Fulcrum, Renovaro top healthcare gainers; Emergent, Geron among losers

2023-08-22 10:00:48 ET Gainers: Fulcrum Therapeutics ( FULC ) +55% . Renovaro Biosciences ( RENB ) +18% . ProMIS Neurosciences ( PMN ) +17% . cbdMD ( YCBD ) +9% . 60 Degrees Pharmaceuticals ( SXTP ) +7% . Losers: Emergent BioSo...

FULC - MINISO Group, Fabrinet, Hollysys Automation Technologies among premarket gainers' pack

2023-08-22 09:27:19 ET Fulcrum Therapeutics ( FULC ) +36% as FDA lifts clinical hold on sickle-cell disease candidate . ProMIS Neurosciences ( PMN ) +30% on $20.4M private placement . Fabrinet ( FN ) +24% on Q4 earnings release . Hallmark Fi...
FULC - Fulcrum climbs as FDA lifts clinical hold on sickle-cell disease candidate

2023-08-22 08:09:03 ET More on Fulcrum Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD Fulcrum inks licensing deal for rare blood disorder Fulcrum slips as Goldman Sachs downgrades on limited catalyst path Fulcrum Therapeutics d...

FULC - FDA Lifts Clinical Hold on Fulcrum Therapeutics' FTX-6058 for Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the U.S. Food and Drug Administration (FDA) ...

FULC - Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Call Transcript

2023-08-05 05:18:06 ET Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Conference Call August 03, 2023, 08:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief Executive Officer Iain Fraser - Interim Chief...
Previous 10 Next 10